Vialwirebiotech, curated
September 30, 2026, 2:44 PM
August 31, 2026
- 12:13 PM · BioPharma Dive12:13 PMFDA OKs Takeda, Protagonist drug for rare blood cancer — BioPharma Dive
- 12:00 PM · BioWorld12:00 PMMFN agreements expand to midsized biopharmas — BioWorld
- 12:00 PM · BioWorld12:00 PMCourt: No harm done when GLP-1s dropped from FDA shortage list — BioWorld
- 12:00 PM · BioWorld12:00 PMA&As: Eva van Rooij to lead Revier; Craig Gibbs new Vivace CEO — BioWorld
- 12:00 PM · BioWorld12:00 PMGraves tending to crowd, Lilly digs in: $2.8B-plus for Merida — BioWorld
- 9:40 AM · Pharmaceutical Technology9:40 AMESC 2026: Aficamten breaks new ground in nonobstructive HCM — Pharmaceutical Technology
- 9:30 AM · SCMP — Tech
- 9:23 AM · Pharmaceutical Executive9:23 AM<![CDATA[BioNTech Terminates Phase II Clinical Trial for Cevumeran ]]> — Pharmaceutical Executive
- 9:17 AM · Pharmaceutical Technology9:17 AMESC 2026: Evolocumab explores new frontiers in CV disease prevention — Pharmaceutical Technology
- 9:09 AM · PharmaVoice
- 9:00 AM · BioWorld9:00 AMDualitybio and Genentech collaborate on DUPAC-based ADCs — BioWorld
- 9:00 AM · BioWorld
August 30, 2026
- 6:00 AM · FT — Pharmaceuticals6:00 AMPharma stocks soar as investors seek AI alternatives — FT — Pharmaceuticals